Abiraterone acetate-associated QT prolongation and torsades de pointes: Postmarketing cases reported to FDA

Abstract

Get full access to this article

View all access options for this article.

References

Zytiga (abiraterone acetate) [package insert]. Horsham, PA: Janssen Biotech, 2020.

Yonsa (abiraterone acetate) [package insert]. Cranbury, NJ: Sun Pharma Global, 2020.

Rodieux

Nieto

Sunthorn

, et al. Abiraterone acetate-induced life-threatening torsade de pointes. Ann Pharmacother 2015; 49: 152–153.

Khan

Kneale

Life threatening torsades de pointes due to abiraterone-induced hypokaelemia in a patient with metastatic prostate cancer. N Z Med J 2016; 129: 124–127.

Attard

Reid

AHM

Yap

, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563–4571.

Center for Drug Evaluation and Research. Pharmacology review NDA 202379. U.S. Food and Drug Administration, www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000PharmR.pdf (2011, accessed 11 March 2021).